-
-
A generic form of paroxetine (PaxilGlaxoSmithKline) will soon be on the market. The drug marks the second SSRI antidepressant to go generic after fluoxetine (Prozac) last year.
-
The prevention of acute chemotherapy-induced nausea and vomiting (CINV) has improved dramatically in the past decade.
-
Malignant pleural mesothelioma (MPM) is an uncommon tumor that carries a dismal prognosis. Its incidence is rising and is expected to continue climbing as more patients reach the end of the 35-40-year lag period between asbestos exposure and tumor development.
-
Twelve cycles of single-agent paclitaxel administered to women with advanced ovarian cancer who attain a clinically defined complete response to initial platinum/paclitaxel-based chemotherapy significantly prolongs the duration of progression-free survival.
-
Evaluations may be based on faulty assumptions; FDA, Customs finds potentially dangerous drug shipments; Color in enteral feeding tube linked to toxicity, death; Antiviral agent causes adverse effects in SARS patients
-
Fuzeon (enfuvirtide), also known as T-20, was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in March 2003. It is the first drug in a unique class of antiretrovirals, known as fusion inhibitors. Enfuvirtide is the newest development in drugs used to treat the human immunodeficiency virus (HIV-1).
-
Adverse drug reactions (ADRs) are common occurrences in hospitals. Historically, the incidence of ADRs in hospitalized patients ranges from 6% to 20%, and 3% to 7% of hospital admissions have been attributed to ADRs.
-
In the Pipeline
-
2003 Salary Survey Results
